A Phase 2, Open-label, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Latest Information Update: 23 Aug 2024
At a glance
- Drugs DZD 8586 (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms TAI-SHAN9
- Sponsors Dizal Pharmaceutical
- 08 Aug 2024 New trial record